Regeneron Pharmaceuticals (REGN) experienced a decline of approximately 2% in premarket trading on Wednesday, despite reporting first-quarter 2026 financial results that surpassed analyst expectations and announcing a new share buyback program valued at up to $3 billion. The company reported Q1 revenue of $3.6 billion, representing year-over-year growth of roughly 19%, which exceeded market consensus estimates for the period. While the positive fundamental data and capital return initiatives should theoretically support equity value, the immediate market reaction was negative. Investors may have been cautious regarding factors not explicitly detailed in the provided snippet, such as pipeline developments, future guidance, or broader market conditions affecting biotech stocks. The discrepancy between the strong operational performance and the stock price drop suggests that other significant news or concerns likely weighed on investor sentiment. This move follows Regeneron's consistent track record of financial performance, with the new buyback program signaling management's confidence in the company's long-term prospects despite short-term volatility. Market participants will likely focus on how these results align with upcoming product launches and competition within key therapeutic areas, which will be crucial for sustaining growth momentum beyond the initial quarter.